key: cord-0796450-1box6noa
authors: Menezes‐Rodrigues, Francisco Sandro; Padrão Tavares, José Gustavo; Pires de Oliveira, Marcelo; Guzella de Carvalho, Rafael; Ruggero Errante, Paolo; Omar Taha, Murched; Fagundes, Djalma José; Caricati‐Neto, Afonso
title: Anticoagulant and antiarrhythmic effects of heparin in the treatment of COVID‐19 patients
date: 2020-05-14
journal: J Thromb Haemost
DOI: 10.1111/jth.14902
sha: 8f63b3cabb3458c07313f8cfcc6f6786358a143d
doc_id: 796450
cord_uid: 1box6noa

Most severe manifestations of COVID‐19 cases, such as multiple organ failure and death, have been linked to coagulation dysfunction markers, such as platelet reduction and increases in prothrombin time, fibrin degradation products and, mainly, D‐dimer [1]. A recent paper by Tang et al. [2] in this journal reported that heparin treatment reduced mortality of COVID‐19 patients with elevated D‐dimer; similar preliminary results have been reported elsewhere [3]. A mounting body of evidence shows that SARS‐CoV‐2 causes a “cytokine storm” [1,4] that activates the coagulation cascade, leading to thrombosis. Similar to the findings in severe sepsis, generalized deposition of intravascular thrombi compromises the blood supply of several organs, leading to organ failure [5].

have been linked to coagulation dysfunction markers, such as platelet reduction and increases in prothrombin time, fibrin degradation products and, mainly, D-dimer [1] . A recent paper by Tang et al. [2] in this journal reported that heparin treatment reduced mortality of COVID-19 patients with elevated D-dimer; similar preliminary results have been reported elsewhere [3] . A mounting body of evidence shows that SARS-CoV-2 causes a "cytokine storm" [1, 4] that activates the coagulation cascade, leading to thrombosis. Similar to the findings in severe sepsis, generalized deposition of intravascular thrombi compromises the blood supply of several organs, leading to organ failure [5] .

Disseminated intravascular coagulation (DIC) secondary to severe infection is classically associated with gram-positive and gram-negative bacteria, malaria and other hemorrhagic fevers, such as hemorrhagic dengue, though SARS-CoV and MERS-CoV have also been shown to trigger DIC. Similar results in COVID-19 [2] [3] [4] now suggest that widespread coagulation events significantly contribute to worse outcomes and patient mortality, which might be attenuated by anticoagulant treatment.

We would also like to add that, while a direct anticoagulant effect is likely crucial to the therapeutic effect of heparin, it also has antiarrhythmic properties [6, 7] that could show promise in the treatment of COVID-19, in which cardiac arrhythmias are the immediate cause of several patient deaths [4] . Heparin oligosaccharides have a marked antiarrhythmic effect in an animal model of heart ischemia-reperfusion, as well as in isolated rat atria, reducing both ventricular arrhythmias and atrioventricular block, likely by increasing Na + -Ca 2+ exchanger activity [6] .

About 16% of COVID-19 patients show cardiac arrhythmias and 7.2% had acute cardiac lesions [4] . Increased cardiac lesion markers, such as interleukin-6, high-sensitivity troponin I (TnI) and lactate dehydrogenase are correlated with poorer patient outcomes [4] . COVID-19

increases TnI and these higher levels correlate with more frequent complications, including malignant ventricular arrhythmias [4] . There are many reports of fulminant myocarditis with cardiogenic shock, associated with atrial and ventricular arrhythmias [1, 4] . In a recent report on Wuhan COVID-19 patients, 16.7% of all hospitalized patients and 44.4% of ICU patients had cardiac arrhythmias [8] . Besides, several drugs proposed for use in the treatment of COVID-19, such as hydroxychloroquine (HCQ), block voltage-gated K + channels, which may cause druginduced long QT syndrome and atrioventricular blocks [9] . Therefore, the concomitant use of HCQ and other antiarrhythmic medications, such as amiodarone or sotalol, may further increase

This article is protected by copyright. All rights reserved the QT interval and require close ECG monitoring. Further characterization of arrhythmic load and mechanisms of death are critical to guide additional treatments and preventive strategies, including the potential role of cardioversion. Azithromycin and other macrolides have also been combined with chloroquine and derivatives in COVID-19 patients, but these antimicrobial drugs also induce long QT [9] . Combined HCQ-azithromycin-treated patients are at an increased risk for druginduced long QT syndrome and torsades des pointes. Lopinavir and ritonavir also prolong PR and QT intervals and may cause severe atrioventricular blocks and torsades de pointes [10] .

Hypokalemia may also increase vulnerability to several tachyarrhythmias and, therefore, COVID-19 patients will likely require close electrolyte and QT monitoring whenever treated with HCQ-azithromycin, due to the interactions of SARS-CoV2 with the renin-angiotensin-aldosterone system and the likelihood of hypokalemia [1, 2] . The American College of Cardiology now offers an easy-to-use calculator to help medical professionals in determining which patients are at an increased risk for ventricular arrhythmias when treated with HCQ-azithromycin. Other HCQ interactions in COVID-19 risk groups may include antihypertensive drugs, such as beta antagonists and Ca 2+ channel blockers, leading to severe bradycardia and cerebral hypoperfusion [9] .

Neither Tang et al. [2] nor Negri et al. [3] report any increase in bleeding with heparin treatment, though this might be a concern with other COVID-19 drug combinations. For instance, lopinavir/ritonavir inhibit CYP3A4 and may drastically increase Xa factor inhibition when combined with apixaban or rivaroxaban [10].

The use of heparins in the treatment of patients with COVID-19 is likely to be beneficial and effective, because it combats the coagulopathies that lead to hypoxia and generalized organ failure, but also because it is likely to attenuate cardiac arrhythmias and sudden deaths associated both with COVID-19 itself or with its pharmacological therapy. It remains to be seen whether other antiarrhythmic drugs also have a role to play in the treatment of COVID-19, at least in patients at higher risk for cardiac arrhythmias.

Cardiac Manifestations Of Coronavirus (COVID-19)

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Heparin therapy improving hypoxia in COVID-19 patients -a case series

Cardiac and arrhythmic complications in patients with COVID-19

The Coagulation and Immune Systems Are Directly Linked through the Activation of Interleukin-1α by Thrombin

Tersariol IL do. S. Heparin Oligosaccharides Have Antiarrhythmic Effect by Accelerating the Sodium-Calcium Exchanger

Straight to the heart: Pleiotropic antiarrhythmic actions of oral anticoagulants

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Mechanisms of drug-induced proarrhythmia in clinical practice